Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:CELU

Celularity Q4 2024 Earnings Report

Celularity logo
$1.38 +0.03 (+2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 -0.02 (-1.81%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Celularity EPS Results

Actual EPS
-$0.59
Consensus EPS
-$1.50
Beat/Miss
Beat by +$0.91
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$18.13 million
Expected Revenue
$5.20 million
Beat/Miss
Beat by +$12.93 million
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q4 2024
Date
5/8/2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Celularity's Q2 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Celularity's Q4 2024 Press ReleasePress Release
(8-K)
Celularity's Q4 2024 Annual reportAnnual report
(10-K)

Celularity Earnings Headlines

Viome CEO Jain to join board of directors at Florham Park-based Celularity
October 1 at 1:48 PM  |  roi-nj.comR
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
September 30 at 11:57 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3372229/0/en/celularity-highlights-anticipated-quarter-one-2027-opening-of-fontaine-vitale-as-strategic-partner.html
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
October 1 at 1:00 AM  |  Decentralized Masters (Ad)
Celularity (NASDAQ:CELU) Releases Quarterly Earnings Results
September 30 at 7:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31069017
Celularity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
September 29 at 10:19 PM  |  marketscreener.comM
Celularity Inc. ernennt Naveen Jain zum Verwaltungsratsmitglied
September 29 at 10:19 PM  |  de.marketscreener.comD
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs. The company has also developed placental-derived biomaterial products intended to support wound care and tissue repair.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. The company was founded by Robert J. Hariri, M.D., Ph.D., who has served in senior leadership roles, including chief executive officer and chairman. Its products and clinical programs are intended for use in the United States and other markets where regulatory authorization or clinical development is available.

View Celularity Profile
Earnings Tools